A blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice

• DOI: 10.1016/j.omtm.2024.101269
• Publication Date: 2024-05-21T02:08:15Z
• Authors: Madison L. Sangster; Martha M. Bishop; Yizheng Yao; Jessica F. Feitor; Sanjid Shahriar; Maxwell E. Miller; Anil K. Chekuri; Bogdan Budnik; Fengfeng Bei; Yulia Grishchuk
• Keywords: 0301 basic medicine; 0303 health sciences; QH573-671; lysosomal disorder; adeno-associated vector; AAV; QH426-470; pediatric neurological disease; Genetics; Original Article; gene transfer; Cytology; TRPML1

Mucolipidosis IV (MLIV) is a rare, autosomal recessive, lysosomal disease characterized by intellectual disability, motor deficits, and progressive vision loss. Using adeno-associated vector 9 (AAV9) and AAV-PHP.B as delivery vectors, we previously demonstrated the feasibility of modifying disease course in a mouse model of MLIV by the human MCOLN1 gene transfer. Here, using a primate-enabling capsid AAV.CPP.16 (CPP16), we constructed a new, clinic-oriented MCOLN1 gene expression vector and demonstrated its efficacy in the preclinical model of MLIV. Systemic administration of CPP16-MCOLN1 in adult symptomatic Mcoln1 -/- mice at a dose of 1e12 vg per mouse resulted in MCOLN1 expression in the brain and peripheral tissues, alleviated brain pathology, rescued neuromotor function, and completely prevented paralysis. Notable expression of MCOLN1 transcripts was also detected in the retina of the mouse, which had exhibited significant degeneration at the time of the treatment. However, no increase in retinal thickness was observed after gene therapy treatment. Our results suggest a new AAV-based systemic gene replacement therapy for the treatment of MLIV that could be translated into clinical studies.